BioCentury | Jul 4, 2011
Company News

GlycoRegImmune, RxMD deal

...The companies partnered to develop new treatments using GlycoRegImmune's natural killer (NK) T cell targeted technologies...
...CROs, to help develop and identify regulatory pathways for GlycoRegImmune's technology. Details were not disclosed. GlycoRegImmune...
...the not-for-profit Torrey Pines Institute for Molecular Studies last month and in July 2009, respectively. GlycoRegImmune Inc....
Items per page:
1 - 1 of 1
BioCentury | Jul 4, 2011
Company News

GlycoRegImmune, RxMD deal

...The companies partnered to develop new treatments using GlycoRegImmune's natural killer (NK) T cell targeted technologies...
...CROs, to help develop and identify regulatory pathways for GlycoRegImmune's technology. Details were not disclosed. GlycoRegImmune...
...the not-for-profit Torrey Pines Institute for Molecular Studies last month and in July 2009, respectively. GlycoRegImmune Inc....
Items per page:
1 - 1 of 1